Caution, this is an AI generated summary based on literature. This may have errors. ?
MIR373 is a microRNA that has been predicted by computational algorithms to regulate several proteins involved in the actin cytoskeleton, including twinfilin-1 and-2, thymosin, and profilin-2 [PMC7408560]. In a study evaluating breast cancer biomarkers, MIR373 was selected as a candidate and its expression levels were assessed in breast cancer patients and healthy individuals [PMC8182592]. Another study found that MIR373 was involved in a subpopulation of chemo-resistant circulating tumor cells (CTCs) with extensive aberrations and marked metastatic ability [PMC8466266]. Additionally, MIR373 levels were found to be upregulated in the substantia nigra of patients with Parkinson's disease, suggesting its involvement in α-synuclein clearance defects [PMC6627933]. These findings highlight the potential role of MIR373 as a regulator of actin cytoskeleton proteins, a biomarker for breast cancer, chemo-resistant CTCs, and Parkinson's disease pathology.